Head to Head Survey: Klaviyo (NYSE:KVYO) vs. Lifeward (NASDAQ:LFWD)

Klaviyo (NYSE:KVYO) and Lifeward (NASDAQ:LFWD) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Profitability

This table compares Klaviyo and Lifeward’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Klaviyo	-6.19%	-1.12%	-0.90%
Lifeward	-121.80%	-137.91%	-90.28%

Analyst Recommendations

This is a breakdown of recent ratings for Klaviyo and Lifeward, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Klaviyo	1	2	19	0	2.82
Lifeward	1	0	3	0	2.50

Klaviyo currently has a consensus price target of $44.30, suggesting a potential upside of 71.45%. Lifeward has a consensus price target of $9.00, suggesting a potential upside of 1,057.41%. Given Lifeward’s higher probable upside, analysts clearly believe Lifeward is more favorable than Klaviyo.

Insider and Institutional Ownership

45.4% of Klaviyo shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 53.2% of Klaviyo shares are owned by insiders. Comparatively, 2.7% of Lifeward shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Klaviyo and Lifeward”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Klaviyo	$937.46 million	8.27	-$46.14 million	($0.25)	-103.35
Lifeward	$25.66 million	0.48	-$28.94 million	($3.12)	-0.25

Lifeward has lower revenue, but higher earnings than Klaviyo. Klaviyo is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Klaviyo has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Lifeward has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

Summary

Klaviyo beats Lifeward on 11 of the 14 factors compared between the two stocks.

About Klaviyo

Klaviyo, Inc., a technology company, provides a software-as-a-service platform in the United States, other Americas, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers Klaviyo, a cloud-native platform for data store, segmentation engine, campaigns and flows, and messaging infrastructure. It also provides email to send personalized marketing emails, including drag-and-drop email templates to edit and customize pre-built templates; email campaigns and automations with smart send time features, generative artificial intelligence for subject line creation, A/B testing tools, and consumer list segmentation; short message services to send targeted marketing text messages to consumers, as well as built-in contact cards to ensure that texts does not appear as random numbers; and push, a personalized push notification to engage with consumer. In addition, the company offers other applications, such as reviews, which collect product reviews; and customer data platform that allows to manage, deploy, transform, and sync data. It serves its products to entrepreneurs, small and medium-sized businesses to mid-market businesses, and enterprises. The was incorporated in 2012 and is headquartered in Boston, Massachusetts.

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.